{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:45:42Z","timestamp":1792842342747,"version":"4.5.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2016\u201000906"],"award-info":[{"award-number":["2016\u201000906"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg foundation","doi-asserted-by":"crossref","award":["2017\u20100383"],"award-info":[{"award-number":["2017\u20100383"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011898","name":"Marianne and Marcus Wallenberg foundation","doi-asserted-by":"crossref","award":["2015.0125"],"award-info":[{"award-number":["2015.0125"]}],"id":[{"id":"10.13039\/501100011898","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson\u2019s disease) at Lund University"},{"name":"Swedish Alzheimer Foundation","award":["AF\u2010939932"],"award-info":[{"award-number":["AF\u2010939932"]}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","award":["FO2021\u20100293"],"award-info":[{"award-number":["FO2021\u20100293"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Parkinson foundation of Sweden","award":["1280\/20"],"award-info":[{"award-number":["1280\/20"]}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sk\u00e5ne University Hospital Foundation","award":["2020\u2010O000028"],"award-info":[{"award-number":["2020\u2010O000028"]}]},{"name":"Regionalt Forskningsst\u00f6d","award":["2020\u20100314"],"award-info":[{"award-number":["2020\u20100314"]}]},{"name":"Swedish federal government under the ALF agreement","award":["2018\u2010Projekt0279"],"award-info":[{"award-number":["2018\u2010Projekt0279"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2022,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever\u2010increasing role in research, clinical trials, and in the clinical work\u2010up of patients. Though cerebrospinal fluid (CSF) and positron emission tomography (PET)\u2010based measures are available, their use is not widespread due to limitations, including high costs and perceived invasiveness. As a result of rapid advances in the development of ultra\u2010sensitive assays, the levels of pathological brain\u2010 and AD\u2010related proteins can now be measured in blood, with recent work showing promising results. Plasma P\u2010tau appears to be the best candidate marker during symptomatic AD (i.e., prodromal AD and AD dementia) and preclinical AD when combined with A\u03b242\/A\u03b240. Though not AD\u2010specific, blood NfL appears promising for the detection of neurodegeneration and could potentially be used to detect the effects of disease\u2010modifying therapies. This review provides an overview of the progress achieved thus far using AD blood\u2010based biomarkers, highlighting key areas of application and unmet challenges.<\/jats:p>","DOI":"10.15252\/emmm.202114408","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T04:26:19Z","timestamp":1638505579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":344,"title":["Blood\u2010based biomarkers for Alzheimer's disease"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4542-7879","authenticated-orcid":false,"given":"Antoine","family":"Leuzy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-7724","authenticated-orcid":false,"given":"Niklas","family":"Mattsson\u2010Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-8378","authenticated-orcid":false,"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-1699","authenticated-orcid":false,"given":"Jeffrey L","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"BFEMMM202114408_CR1","unstructured":"(1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's disease. Neurobiol Aging 18: S1\u2013S2"},{"key":"BFEMMM202114408_CR2","first-page":"965","volume":"320","author":"J Abbasi","year":"2018","unstructured":"Abbasi J (2018) Promising results in 18\u2010month analysis of Alzheimer drug candidate. JAMA 320: 965","journal-title":"JAMA"},{"key":"BFEMMM202114408_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13195-019-0562-4","volume":"12","author":"S Abu\u2010Rumeileh","year":"2019","unstructured":"Abu\u2010Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti\u2010Stella A, Oeckl P, Baiardi S, Zenesini C, Huss A, Cortelli P et\u00a0al (2019) CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther 12: 2","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114408_CR4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC et\u00a0al (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging\u2010Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270\u2013279","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40263-017-0483-3","volume":"31","author":"A Ardura\u2010Fabregat","year":"2017","unstructured":"Ardura\u2010Fabregat A, Boddeke EWGM, Boza\u2010Serrano A, Brioschi S, Castro\u2010Gomez S, Ceyz\u00e9riat K, Dansokho C, Dierkes T, Gelders G, Heneka MT et\u00a0al (2017) Targeting neuroinflammation to treat Alzheimer's disease. CNS Drugs 31: 1057\u20131082","journal-title":"CNS Drugs"},{"key":"BFEMMM202114408_CR6","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet AL, Pascoal TA, Lle\u00f3 A, Parnetti L et\u00a0al (2021a) A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 12: 3400","journal-title":"Nat Commun"},{"key":"BFEMMM202114408_CR7","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1007\/s00259-021-05253-y","volume":"48","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Leuzy A, Karikari TK, Mattsson\u2010Carlgren N, Dodich A, Boccardi M, Corre J, Drzezga A, Nordberg A, Ossenkoppele R et\u00a0al (2021b) The validation status of blood biomarkers of amyloid and phospho\u2010tau assessed with the 5\u2010phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging 48: 2140\u20132156","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"BFEMMM202114408_CR8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero\u2010Rodriguez J, Brinkmalm G, Snellman A, Sch\u00f6ll M, Troakes C, Hye A et\u00a0al (2021c) Plasma p\u2010tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol 141: 709\u2013724","journal-title":"Acta Neuropathol"},{"key":"BFEMMM202114408_CR9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010. J Neuropathol Exp Neurol 71: 266\u2013273","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFEMMM202114408_CR10","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1093\/brain\/awaa342","volume":"143","author":"AL Benedet","year":"2020","unstructured":"Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M, Therriault J, Kang MS, Chamoun M, Sch\u00f6ll M et\u00a0al (2020) Stage\u2010specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. Brain 143: 3793\u20133804","journal-title":"Brain"},{"key":"BFEMMM202114408_CR11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2: 605\u2013613","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","volume":"11","author":"K Blennow","year":"2015","unstructured":"Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 11: 58\u201369","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR13","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00259-020-05120-2","volume":"48","author":"M Boccardi","year":"2021","unstructured":"Boccardi M, Dodich A, Albanese E, Gayet\u2010Ageron A, Festari C, Ashton NJ, Bischof GN, Chiotis K, Leuzy A, Wolters EE et\u00a0al (2021) The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging 48: 2070\u20132085","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"BFEMMM202114408_CR14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1176\/appi.ajp.160.2.376","volume":"160","author":"K Buerger","year":"2003","unstructured":"Buerger K, Zinkowski R, Teipel SJ, Arai H, DeBernardis J, Kerkman D, McCulloch C, Padberg F, Faltraco F, Goernitz A et\u00a0al (2003) Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry 160: 376\u2013379","journal-title":"Am J Psychiatry"},{"key":"BFEMMM202114408_CR15","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","volume":"129","author":"K Buerger","year":"2006","unstructured":"Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H et\u00a0al (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129: 3035\u20133041","journal-title":"Brain"},{"key":"BFEMMM202114408_CR16","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awm140","volume":"130","author":"K Buerger","year":"2007","unstructured":"Buerger K, Alafuzoff I, Ewers M, Pirttila T, Zinkowski R, Hampel H (2007) No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 130: e82","journal-title":"Brain"},{"key":"BFEMMM202114408_CR17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P (2016) Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement 12: 719\u2013732","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.molmed.2018.11.006","volume":"25","author":"SF Carter","year":"2019","unstructured":"Carter SF, Herholz K, Rosa\u2010Neto P, Pellerin L, Nordberg A, Zimmer ER (2019) Astrocyte biomarkers in Alzheimer's disease. Trends Mol Med 25: 77\u201395","journal-title":"Trends Mol Med"},{"key":"BFEMMM202114408_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","volume":"11","author":"P Chatterjee","year":"2021","unstructured":"Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, Verberk IMW, Dave P, Taddei K, Sohrabi HR et\u00a0al (2021) Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. Transl Psychiatry 11: 27","journal-title":"Transl Psychiatry"},{"key":"BFEMMM202114408_CR20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41398-021-01476-7","volume":"11","author":"SD Chen","year":"2021","unstructured":"Chen SD, Huang YY, Shen XN, Guo Y, Tan L, Dong Q, Yu JT, Alzheimer's Disease Neuroimaging Initiative (2021) Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease. Transl Psychiatry 11: 356","journal-title":"Transl Psychiatry"},{"key":"BFEMMM202114408_CR21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson\u2010Carlgren N, Hansson O (2021) Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther 13: 68","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114408_CR22","doi-asserted-by":"crossref","first-page":"8844","DOI":"10.1523\/JNEUROSCI.23-26-08844.2003","volume":"23","author":"JR Cirrito","year":"2003","unstructured":"Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM et\u00a0al (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque\u2010associated changes in amyloid\u2010beta metabolism and half\u2010life. J Neurosci 23: 8844\u20138853","journal-title":"J Neurosci"},{"key":"BFEMMM202114408_CR23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P, Sarasa L, Allu\u00e9 JA, Proctor NK, Zetterberg H et\u00a0al (2021a) Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging 1: 114\u2013123","journal-title":"Nat Aging"},{"key":"BFEMMM202114408_CR24","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","volume":"12","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Janelidze S, Palmqvist S, Svenningsson AL, Stomrud E, Dage JL, Mattsson\u2010Carlgren N, Hansson O (2021b) Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun 12: 3555","journal-title":"Nat Commun"},{"key":"BFEMMM202114408_CR25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","volume":"1118","author":"J Cummings","year":"2019","unstructured":"Cummings J (2019) The role of biomarkers in Alzheimer's disease drug development. Adv Exp Med Biol 1118: 29\u201361","journal-title":"Adv Exp Med Biol"},{"key":"BFEMMM202114408_CR26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13195-020-00728-w","volume":"12","author":"S De Meyer","year":"2020","unstructured":"De Meyer S, Schaeverbeke JM, Verberk IMW, Gille B, De Schaepdryver M, Luckett ES, Gabel S, Bruffaerts R, Mauroo K, Thijssen EH et\u00a0al (2020) Comparison of ELISA\u2010 and SIMOA\u2010based quantification of plasma Abeta ratios for early detection of cerebral amyloidosis. Alzheimers Res Ther 12: 162","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114408_CR27","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/brain\/awaa054","volume":"143","author":"F de Wolf","year":"2020","unstructured":"de Wolf F, Ghanbari M, Licher S, McRae\u2010McKee K, Gras L, Weverling GJ, Wermeling P, Sedaghat S, Ikram MK, Waziry R et\u00a0al (2020) Plasma tau, neurofilament light chain and amyloid\u2010beta levels and risk of dementia; a population\u2010based cohort study. Brain 143: 1220\u20131232","journal-title":"Brain"},{"key":"BFEMMM202114408_CR28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Sch\u00e4delin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D et\u00a0al (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81: 857\u2013870","journal-title":"Ann Neurol"},{"key":"BFEMMM202114408_CR29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.parkreldis.2018.06.018","volume":"56","author":"L Donker Kaat","year":"2018","unstructured":"Donker Kaat L, Meeter LH, Chiu WZ, Melhem S, Boon AJW, Blennow K, Zetterberg H, van Swieten JC (2018) Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat Disord 56: 98\u2013101","journal-title":"Parkinsonism Relat Disord"},{"key":"BFEMMM202114408_CR30","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger\u2010Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G et\u00a0al (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS\u2010ADRDA criteria. Lancet Neurol 6: 734\u2013746","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R et\u00a0al (2014) Advancing research diagnostic criteria for Alzheimer's disease: the IWG\u20102 criteria. Lancet Neurol 13: 614\u2013629","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jalz.2015.08.003","volume":"12","author":"FH Duits","year":"2016","unstructured":"Duits FH, Martinez\u2010Lage P, Paquet C, Engelborghs S, Lle\u00f3 A, Hausner L, Molinuevo JL, Stomrud E, Farotti L, Ramakers IHGB et\u00a0al (2016) Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement 12: 154\u2013163","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR33","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90: 870\u2013881","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFEMMM202114408_CR34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/nan.12338","volume":"43","author":"CJ Garwood","year":"2017","unstructured":"Garwood CJ, Ratcliffe LE, Simpson JE, Heath PR, Ince PG, Wharton SB (2017) Review: astrocytes in Alzheimer's disease and other age\u2010associated dementias: a supporting player with a central role. Neuropathol Appl Neurobiol 43: 281\u2013298","journal-title":"Neuropathol Appl Neurobiol"},{"key":"BFEMMM202114408_CR35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gisslen","year":"2016","unstructured":"Gisslen M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H (2016) Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross\u2010sectional study. EBioMedicine 3: 135\u2013140","journal-title":"EBioMedicine"},{"key":"BFEMMM202114408_CR36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.28634","volume":"3","author":"KV Giudici","year":"2020","unstructured":"Giudici KV, de Souto Barreto P, Guyonnet S, Li Y, Bateman RJ, Vellas B, MAPT\/DSA Group (2020) Assessment of plasma amyloid\u2010beta42\/40 and cognitive decline among community\u2010dwelling older adults. JAMA Netw Open 3: e2028634","journal-title":"JAMA Netw Open"},{"key":"BFEMMM202114408_CR37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/medethics-2019-105586","volume":"46","author":"T Grote","year":"2020","unstructured":"Grote T, Berens P (2020) On the ethics of algorithmic decision\u2010making in healthcare. J Med Ethics 46: 205\u2013211","journal-title":"J Med Ethics"},{"key":"BFEMMM202114408_CR38","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","volume":"261","author":"I Grundke\u2010Iqbal","year":"1986","unstructured":"Grundke\u2010Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986a) Microtubule\u2010associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084\u20136089","journal-title":"J Biol Chem"},{"key":"BFEMMM202114408_CR39","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke\u2010Iqbal","year":"1986","unstructured":"Grundke\u2010Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986b) Abnormal phosphorylation of the microtubule\u2010associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83: 4913\u20134917","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM202114408_CR40","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","volume":"9","author":"H Hampel","year":"2010","unstructured":"Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde ALW, Jessen F, Hoessler YC et\u00a0al (2010) Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9: 560\u2013574","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM202114408_CR41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jalz.2012.05.2116","volume":"8","author":"H Hampel","year":"2012","unstructured":"Hampel H, Lista S, Khachaturian ZS (2012) Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 8: 312\u2013336","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/joim.12822","volume":"284","author":"GS Handelman","year":"2018","unstructured":"Handelman GS, Kok HK, Chandra RV, Razavi AH, Lee MJ, Asadi H (2018) eDoctor: machine learning and the future of medicine. J Intern Med 284: 603\u2013619","journal-title":"J Intern Med"},{"key":"BFEMMM202114408_CR43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.neurobiolaging.2008.03.027","volume":"31","author":"O Hansson","year":"2010","unstructured":"Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31: 357\u2013367","journal-title":"Neurobiol Aging"},{"key":"BFEMMM202114408_CR44","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R et\u00a0al (2018) CSF biomarkers of Alzheimer's disease concord with amyloid\u2010beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14: 1470\u20131481","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P (2019) Advantages and disadvantages of the use of the CSF amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer's disease. Alzheimers Res Ther 11: 34","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114408_CR46","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41598-020-80274-5","volume":"11","author":"L He","year":"2021","unstructured":"He L, Morley JE, Aggarwal G, Nguyen AD, Vellas B, de Souto Barreto P, MAPT\/DSA Group (2021) Plasma neurofilament light chain is associated with cognitive decline in non\u2010dementia older adults. Sci Rep 11: 128","journal-title":"Sci Rep"},{"key":"BFEMMM202114408_CR47","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1073\/pnas.84.10.3472","volume":"84","author":"PN Hoffman","year":"1987","unstructured":"Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DL (1987) Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci USA 84: 3472\u20133476","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM202114408_CR48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ceb.2015.02.004","volume":"32","author":"EM Hol","year":"2015","unstructured":"Hol EM, Pekny M (2015) Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol 32: 121\u2013130","journal-title":"Curr Opin Cell Biol"},{"key":"BFEMMM202114408_CR49","first-page":"e671","volume":"96","author":"I Illan\u2010Gala","year":"2021","unstructured":"Illan\u2010Gala I, Lleo A, Karydas A, Staffaroni AM, Zetterberg H, Sivasankaran R, Grinberg LT, Spina S, Kramer JH, Ramos EM et\u00a0al (2021) Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology 96: e671\u2013e683","journal-title":"Neurology"},{"issue":"Suppl 1","key":"BFEMMM202114408_CR50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1017\/S1041610297005024","volume":"9","author":"K Iqbal","year":"1997","unstructured":"Iqbal K, Grundke\u2010Iqbal I (1997) Elevated levels of tau and ubiquitin in brain and cerebrospinal fluid in Alzheimer's disease. Int Psychogeriatr 9(Suppl 1): 289\u2013296; discussion 317\u2013221","journal-title":"Int Psychogeriatr"},{"key":"BFEMMM202114408_CR51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/jnc.13399","volume":"136","author":"A Ishiki","year":"2016","unstructured":"Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, Arai H, Furukawa K (2016) Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem 136: 258\u2013261","journal-title":"J Neurochem"},{"key":"BFEMMM202114408_CR52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"T Iwatsubo","year":"1994","unstructured":"Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end\u2010specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13: 45\u201353","journal-title":"Neuron"},{"key":"BFEMMM202114408_CR53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack Jr","year":"2011","unstructured":"Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging\u2010Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 257\u2013262","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR54","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS et\u00a0al (2016) A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87: 539\u2013547","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J et\u00a0al (2018) NIA\u2010AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 14: 535\u2013562","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR56","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(20)30112-5","volume":"19","author":"CR Jack Jr","year":"2020","unstructured":"Jack Jr CR (2020) The transformative potential of plasma phosphorylated tau. Lancet Neurol 19: 373\u2013374","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR57","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir CA, Baker D et\u00a0al (2016) Plasma beta\u2010amyloid in Alzheimer's disease and vascular disease. Sci Rep 6: 26801","journal-title":"Sci Rep"},{"key":"BFEMMM202114408_CR58","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H et\u00a0al (2020a) Plasma P\u2010tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med 26: 379\u2013386","journal-title":"Nat Med"},{"key":"BFEMMM202114408_CR59","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, Proctor NK, Chai X, Shcherbinin S, Sims JR et\u00a0al (2020b) Cerebrospinal fluid p\u2010tau217 performs better than p\u2010tau181 as a biomarker of Alzheimer's disease. Nat Commun 11: 1683","journal-title":"Nat Commun"},{"key":"BFEMMM202114408_CR60","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allue JA, Sarasa L, Eichenlaub U, Bittner T, Ovod V, Verberk IMW, Toba K et\u00a0al (2021) Head\u2010to\u2010head comparison of 8 plasma amyloid\u2010beta 42\/40 assays in Alzheimer disease. JAMA Neurol 78: 1375\u20131382","journal-title":"JAMA Neurol"},{"key":"BFEMMM202114408_CR61","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM et\u00a0al (2013) Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 9: e\u20101\u201016","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR62","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suarez\u2010Calvet M, Saha\u2010Chaudhuri P, Lussier F, Kvartsberg H, Rial AM et\u00a0al (2021) Diagnostic performance and prediction of clinical progression of plasma phospho\u2010tau181 in the Alzheimer's disease neuroimaging initiative. Mol Psychiatry 26: 429\u2013442","journal-title":"Mol Psychiatry"},{"key":"BFEMMM202114408_CR63","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/alz.12236","volume":"17","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Emer\u0161i\u010d A, Vrillon A, Lantero\u2010Rodriguez J, Ashton NJ, Kramberger MG, Dumurgier J, Hourregue C, \u010cu\u010dnik S, Brinkmalm G et\u00a0al (2020a) Head\u2010to\u2010head comparison of clinical performance of CSF phospho\u2010tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimers Dement 17: 755\u2013767","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR64","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J et\u00a0al (2020b) Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19: 422\u2013433","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR65","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F et\u00a0al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14: 577\u2013589","journal-title":"Nat Rev Neurol"},{"key":"BFEMMM202114408_CR66","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L (2019) Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92: e1007\u2013e1015","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR67","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1006\/bbrc.1999.0552","volume":"257","author":"YM Kuo","year":"1999","unstructured":"Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Woods AS, Cotter RJ, Roher AE (1999) High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 257: 787\u2013791","journal-title":"Biochem Biophys Res Commun"},{"key":"BFEMMM202114408_CR68","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0002-9440(10)64947-4","volume":"156","author":"YM Kuo","year":"2000","unstructured":"Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, Kalback WM, Emmerling MR, Beach TG, Roher AE (2000) Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol 156: 797\u2013805","journal-title":"Am J Pathol"},{"key":"BFEMMM202114408_CR69","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1212\/WNL.0000000000004860","volume":"90","author":"R La Joie","year":"2018","unstructured":"La Joie R, Bejanin A, Fagan AM, Ayakta N, Baker SL, Bourakova V, Boxer AL, Cha J, Karydas A, Jerome G et\u00a0al (2018) Associations between [(18)F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90: e282\u2013e290","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR70","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12603-009-0062-5","volume":"13","author":"DR Lachno","year":"2009","unstructured":"Lachno DR, Vanderstichele H, De Groote G, Kostanjevecki V, De Meyer G, Siemers ER, Willey MB, Bourdage JS, Konrad RJ, Dean RA (2009) The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta\u2010amyloid isoforms using the INNO\u2010BIA plasma Abeta forms multiplex assay. J Nutr Health Aging 13: 220\u2013225","journal-title":"J Nutr Health Aging"},{"key":"BFEMMM202114408_CR71","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez J, Karikari TK, Suarez\u2010Calvet M, Troakes C, King A, Emersic A, Aarsland D, Hye A, Zetterberg H, Blennow K et\u00a0al (2020) Plasma p\u2010tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post\u2010mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol 140: 267\u2013278","journal-title":"Acta Neuropathol"},{"key":"BFEMMM202114408_CR72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","volume":"11","author":"MJ Leitao","year":"2019","unstructured":"Leitao MJ, Silva\u2010Spinola A, Santana I, Olmedo V, Nadal A, Le Bastard N, Baldeiras I (2019) Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. Alzheimers Res Ther 11: 91","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114408_CR73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","volume":"10","author":"P Lewczuk","year":"2018","unstructured":"Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P, Maler JM, Kornhuber J, Blennow K, Zetterberg H (2018) Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther 10: 71","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114408_CR74","first-page":"461","volume":"78","author":"QX Li","year":"1998","unstructured":"Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL (1998) Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Lab Invest 78: 461\u2013469","journal-title":"Lab Invest"},{"key":"BFEMMM202114408_CR75","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40120-019-00164-5","volume":"8","author":"D Li","year":"2019","unstructured":"Li D, Mielke MM (2019) An update on blood\u2010based markers of alzheimer's disease using the SiMoA platform. Neurol Ther 8: 73\u201382","journal-title":"Neurol Ther"},{"key":"BFEMMM202114408_CR76","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clinbiochem.2019.05.005","volume":"72","author":"V Lifke","year":"2019","unstructured":"Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL et\u00a0al (2019) Elecsys((R)) Total\u2010Tau and Phospho\u2010Tau (181P) CSF assays: analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clin Biochem 72: 30\u201338","journal-title":"Clin Biochem"},{"key":"BFEMMM202114408_CR77","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1212\/01.wnl.0000306696.82017.66","volume":"70","author":"OL Lopez","year":"2008","unstructured":"Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70: 1664\u20131671","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR79","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/jme.26.2.108","volume":"26","author":"M Marzanski","year":"2000","unstructured":"Marzanski M (2000) Would you like to know what is wrong with you? On telling the truth to patients with dementia. J Med Ethics 26: 108\u2013113","journal-title":"J Med Ethics"},{"key":"BFEMMM202114408_CR80","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer's Disease Neuroimaging Initiative (2017a) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 74: 557\u2013566","journal-title":"JAMA Neurol"},{"key":"BFEMMM202114408_CR81","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.15252\/emmm.201707809","volume":"9","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Scholl M, Strandberg O, Smith R, Palmqvist S, Insel PS, Hagerstrom D, Ohlsson T, Zetterberg H, Jogi J et\u00a0al (2017b) (18)F\u2010AV\u20101451 and CSF T\u2010tau and P\u2010tau as biomarkers in Alzheimer's disease. EMBO Mol Med 9: 1212\u20131223","journal-title":"EMBO Mol Med"},{"key":"BFEMMM202114408_CR82","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K (2019) Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 76: 791\u2013799","journal-title":"JAMA Neurol"},{"key":"BFEMMM202114408_CR83","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson\u2010Carlgren","year":"2020","unstructured":"Mattsson\u2010Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, Zetterberg H, Rosen HJ, Rabinovici G, Chai X et\u00a0al (2020a) Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Sci Adv 6: eaaz2387","journal-title":"Sci Adv"},{"key":"BFEMMM202114408_CR84","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson\u2010Carlgren","year":"2020","unstructured":"Mattsson\u2010Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, Mengel D, Walsh DM, Stomrud E, Dage JL et\u00a0al (2020b) Longitudinal plasma p\u2010tau217 is increased in early stages of Alzheimer's disease. Brain 143: 3234\u20133241","journal-title":"Brain"},{"key":"BFEMMM202114408_CR85","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1038\/s41467-020-19957-6","volume":"11","author":"N Mattsson\u2010Carlgren","year":"2020","unstructured":"Mattsson\u2010Carlgren N, Palmqvist S, Blennow K, Hansson O (2020c) Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nat Commun 11: 6252","journal-title":"Nat Commun"},{"key":"BFEMMM202114408_CR86","doi-asserted-by":"crossref","first-page":"e14022","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson\u2010Carlgren","year":"2021","unstructured":"Mattsson\u2010Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, Reiman EM, Palmqvist S, Dage JL, Beach TG et\u00a0al (2021) Soluble P\u2010tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med 13: e14022","journal-title":"EMBO Mol Med"},{"key":"BFEMMM202114408_CR87","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1001\/jamaneurol.2017.2712","volume":"74","author":"IS van Maurik","year":"2017","unstructured":"van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM et\u00a0al (2017) Interpreting biomarker results in individual patients with mild cognitive impairment in the Alzheimer's biomarkers in daily practice (ABIDE) project. JAMA Neurol 74: 1481\u20131491","journal-title":"JAMA Neurol"},{"key":"BFEMMM202114408_CR88","doi-asserted-by":"crossref","DOI":"10.2196\/13417","volume":"3","author":"IS van Maurik","year":"2019","unstructured":"van Maurik IS, Visser LNC, Pel\u2010Littel RE, van Buchem MM, Zwan MD, Kunneman M, Pelkmans W, Bouwman FH, Minkman M, Schoonenboom N et\u00a0al (2019a) Development and usability of ADappt: web\u2010based tool to support clinicians, patients, and caregivers in the diagnosis of mild\u00a0cognitive impairment and alzheimer disease. JMIR Form Res 3: e13417","journal-title":"JMIR Form Res"},{"key":"BFEMMM202114408_CR89","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1474-4422(19)30283-2","volume":"18","author":"IS van Maurik","year":"2019","unstructured":"van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J et\u00a0al (2019b) Biomarker\u2010based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol 18: 1034\u20131044","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR90","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R et\u00a0al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging\u2010Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263\u2013269","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR91","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jnc.14574","volume":"148","author":"F Michetti","year":"2019","unstructured":"Michetti F, D'Ambrosi N, Toesca A, Puglisi MA, Serrano A, Marchese E, Corvino V, Geloso MC (2019) The S100B story: from biomarker to active factor in neural injury. J Neurochem 148: 168\u2013187","journal-title":"J Neurochem"},{"key":"BFEMMM202114408_CR92","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, Airey DC, Knopman DS, Roberts RO, Machulda MM et\u00a0al (2018) Plasma phospho\u2010tau181 increases with Alzheimer's disease clinical severity and is associated with tau\u2010 and amyloid\u2010positron emission tomography. Alzheimers Dement 14: 989\u2013997","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR93","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","volume":"93","author":"MM Mielke","year":"2019","unstructured":"Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, Machulda MM, Kremers WK, Knopman DS, Jack C et\u00a0al (2019) Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology 93: e252\u2013e260","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR94","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479\u2013486","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR95","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","volume":"78","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodriguez J, Snellman A, Suarez\u2010Calvet M, Blennow K, Zetterberg H, Scholl M et\u00a0al (2021) Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol 78: 396\u2013406","journal-title":"JAMA Neurol"},{"key":"BFEMMM202114408_CR96","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","volume":"38","author":"R Motter","year":"1995","unstructured":"Motter R, Vigo\u2010Pelfrey C, Kholodenko D, Barbour R, Johnson\u2010Wood K, Galasko D, Chang L, Miller B, Clark C, Green R et\u00a0al (1995) Reduction of beta\u2010amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38: 643\u2013648","journal-title":"Ann Neurol"},{"key":"BFEMMM202114408_CR97","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, Fowler C, Li QX, Martins R, Rowe C et\u00a0al (2018) High performance plasma amyloid\u2010beta biomarkers for Alzheimer's disease. Nature 554: 249\u2013254","journal-title":"Nature"},{"key":"BFEMMM202114408_CR98","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0006-8993(03)03219-0","volume":"987","author":"N Norgren","year":"2003","unstructured":"Norgren N, Rosengren L, Stigbrand T (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987: 25\u201331","journal-title":"Brain Res"},{"key":"BFEMMM202114408_CR99","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Halbgebauer S, Anderl\u2010Straub S, Steinacker P, Huss AM, Neugebauer H, von Arnim CAF, Diehl\u2010Schmid J, Grimmer T, Kornhuber J et\u00a0al (2019) Glial fibrillary acidic protein in serum is increased in Alzheimer's disease\u00a0and correlates with cognitive impairment. J Alzheimers Dis 67: 481\u2013488","journal-title":"J Alzheimers Dis"},{"key":"BFEMMM202114408_CR100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, H\u00f6ltt\u00e4 M, Ros\u00e9n C, Olsson C, Strobel G et\u00a0al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta\u2010analysis. Lancet Neurol 15: 673\u2013684","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR101","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"B Olsson","year":"2019","unstructured":"Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, Rostasy K, Blennow K, Zetterberg H, Tulinius M (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 266: 2129\u20132136","journal-title":"J Neurol"},{"key":"BFEMMM202114408_CR102","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P et\u00a0al (2017) A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers Res Ther 9: 95","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114408_CR103","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC et\u00a0al (2017) Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13: 841\u2013849","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR104","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jalz.2018.08.014","volume":"15","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Zetterberg H, Blennow K, Brix B, Stomrud E, Alzheimer's Disease Neuroimaging Initiative, Fs SB, Mattsson N, Hansson O (2019a) Accurate risk estimation of beta\u2010amyloid positivity to identify prodromal Alzheimer's disease: Cross\u2010validation study of practical algorithms. Alzheimers Dement 15: 194\u2013204","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR105","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K et\u00a0al (2019b) Performance of fully automated plasma assays as screening tests for Alzheimer disease\u2010related beta\u2010amyloid status. JAMA Neurol 76: 1060\u20131069","journal-title":"JAMA Neurol"},{"key":"BFEMMM202114408_CR106","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su YI, Chen Y, Serrano GE, Leuzy A et\u00a0al (2020) Discriminative accuracy of plasma phospho\u2010tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324: 772","journal-title":"JAMA"},{"key":"BFEMMM202114408_CR107","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2014.04.041","volume":"573","author":"J Pannee","year":"2014","unstructured":"Pannee J, Tornqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G, Persson R, Gobom J, Svensson J, Johansson P et\u00a0al (2014) The amyloid\u2010beta degradation pattern in plasma\u2013a possible tool for clinical trials in Alzheimer's disease. Neurosci Lett 573: 7\u201312","journal-title":"Neurosci Lett"},{"key":"BFEMMM202114408_CR108","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab223","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson\u2010Carlgren N, Palmqvist S, Teunissen CE, Zetterberg H, Stomrud E, Ashton NJ, Blennow K et\u00a0al (2021a) Plasma GFAP is an early marker of amyloid\u2010beta but not tau pathology in Alzheimer's disease. Brain https:\/\/doi.org\/10.1093\/brain\/awab223","journal-title":"Brain"},{"key":"BFEMMM202114408_CR109","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/brain\/awab163","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Stomrud E, Palmqvist S, van Westen D, Dage JL, Mattsson\u2010Carlgren N, Hansson O (2021b) Plasma markers predict changes in amyloid, tau, atrophy and cognition in non\u2010demented subjects. Brain 144: 2826\u20132836","journal-title":"Brain"},{"key":"BFEMMM202114408_CR110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.14283\/jpad.2018.41","volume":"6","author":"V Perez\u2010Grijalba","year":"2019","unstructured":"Perez\u2010Grijalba V, Romero J, Pesini P, Sarasa L, Monleon I, San\u2010Jose I, Arbizu J, Martinez\u2010Lage P, Munuera J, Ruiz A et\u00a0al (2019) Plasma Abeta42\/40 ratio detects early stages of Alzheimer's disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. J Prev Alzheimers Dis 6: 34\u201341","journal-title":"J Prev Alzheimers Dis"},{"key":"BFEMMM202114408_CR111","volume":"2012","author":"P Pesini","year":"2012","unstructured":"Pesini P, Perez\u2010Grijalba V, Monleon I, Boada M, Tarraga L, Martinez\u2010Lage P, San\u2010Jose I, Sarasa M (2012) Reliable measurements of the beta\u2010amyloid pool in blood could help in the early diagnosis of AD. Int J Alzheimers Dis 2012: 604141","journal-title":"Int J Alzheimers Dis"},{"key":"BFEMMM202114408_CR112","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/pr7008669","volume":"7","author":"E Portelius","year":"2008","unstructured":"Portelius E, Hansson SF, Tran AJ, Zetterberg H, Grognet P, Vanmechelen E, H\u00f6glund K, Brinkmalm G, Westman\u2010Brinkmalm A, Nordhoff E et\u00a0al (2008) Characterization of tau in cerebrospinal fluid using mass spectrometry. J Proteome Res 7: 2114\u20132120","journal-title":"J Proteome Res"},{"key":"BFEMMM202114408_CR113","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gr\u00e4ber S, Kuder\u2010Buletta E, LaFougere C, Laske C et\u00a0al (2019) Serum neurofilament\u00a0dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med 25: 277\u2013283","journal-title":"Nat Med"},{"key":"BFEMMM202114408_CR114","unstructured":"Prince M, Comas\u2010Herrera A, Knapp M, Guerchet M & Karagiannidou M (2016) World Alzheimer Report 2016: Improving healthcare for people with dementia. https:\/\/www.alz.co.uk\/research\/"},{"key":"BFEMMM202114408_CR115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(20)30137-X","volume":"19","author":"YT Quiroz","year":"2020","unstructured":"Quiroz YT, Zetterberg H, Reiman EM, Chen Y, Su YI, Fox\u2010Fuller JT, Garcia G, Villegas A, Sepulveda\u2010Falla D, Villada M et\u00a0al (2020) Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross\u2010sectional and longitudinal cohort study. Lancet Neurol 19: 513\u2013521","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR116","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman\u2010Segev OH et\u00a0al (2019) Association of amyloid positron emission tomography with subsequent\u00a0change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321: 1286\u20131294","journal-title":"JAMA"},{"key":"BFEMMM202114408_CR117","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jalz.2012.12.006","volume":"10","author":"A Rembach","year":"2014","unstructured":"Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li Q\u2010X et\u00a0al (2014) Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement 10: 53\u201361","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR118","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel PP, Chang L, Rivnak AJ et\u00a0al (2010) Single\u2010molecule enzyme\u2010linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28: 595\u2013599","journal-title":"Nat Biotechnol"},{"key":"BFEMMM202114408_CR119","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1021\/ac103161b","volume":"83","author":"DM Rissin","year":"2011","unstructured":"Rissin DM, Fournier DR, Piech T, Kan CW, Campbell TG, Song L, Chang L, Rivnak AJ, Patel PP, Provuncher GK et\u00a0al (2011) Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range. Anal Chem 83: 2279\u20132285","journal-title":"Anal Chem"},{"key":"BFEMMM202114408_CR120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jalz.2008.10.004","volume":"5","author":"AE Roher","year":"2009","unstructured":"Roher AE, Esh CL, Kokjohn TA, Casta\u00f1o EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo Y\u2010M et\u00a0al (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5: 18\u201329","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR121","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IOC, Dick KM, Brotherhood E, Gordon E, Fellows A, Toombs J, Druyeh R, Cardoso MJ, Ourselin S et\u00a0al (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87: 1329\u20131336","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR122","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.dadm.2019.02.002","volume":"11","author":"M Rozga","year":"2019","unstructured":"Rozga M, Bittner T, Batrla R, Karl J (2019) Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers. Alzheimers Dement (Amst) 11: 291\u2013300","journal-title":"Alzheimers Dement (Amst)"},{"key":"BFEMMM202114408_CR123","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S et\u00a0al (2014) Two phase 3 trials of bapineuzumab in mild\u2010to\u2010moderate Alzheimer's disease. N Engl J Med 370: 322\u2013333","journal-title":"N Engl J Med"},{"key":"BFEMMM202114408_CR124","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neuron.2018.04.035","volume":"98","author":"C Sato","year":"2018","unstructured":"Sato C, Barth\u00e9lemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel\u2010Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM et\u00a0al (2018) Tau kinetics in neurons and the human central nervous system. Neuron 98: 861\u2013864","journal-title":"Neuron"},{"key":"BFEMMM202114408_CR125","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C et\u00a0al (2019) High\u2010precision plasma beta\u2010amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93: e1647\u2013e1659","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR126","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1212\/WNL.0b013e3182563bd0","volume":"78","author":"TT Seppala","year":"2012","unstructured":"Seppala TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, Pyykko OT, Helisalmi S, Alafuzoff I, Hiltunen M et\u00a0al (2012) CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 78: 1568\u20131575","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR127","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","volume":"14","author":"LM Shaw","year":"2018","unstructured":"Shaw LM, Arias J, Blennow K, Galasko D, Molinuevo JL, Salloway S, Schindler S, Carrillo MC, Hendrix JA, Ross A et\u00a0al (2018) Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimers Dement 14: 1505\u20131521","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR128","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simr\u00e9n","year":"2021","unstructured":"Simr\u00e9n J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero\u2010Rodriguez J, Mattsson\u2010Carlgren N, Sch\u00f6ll M, Mecocci P, Vellas B et\u00a0al (2021) The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimers Dement 17: 1145\u20131156","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3233\/JAD-2011-101977","volume":"26","author":"F Song","year":"2011","unstructured":"Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS (2011) Meta\u2010analysis of plasma amyloid\u2010beta levels in Alzheimer's disease. J Alzheimers Dis 26: 365\u2013375","journal-title":"J Alzheimers Dis"},{"key":"BFEMMM202114408_CR130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ et\u00a0al (2011a) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging\u2010Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280\u2013292","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR131","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002609","volume":"3","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack Jr CR, Aisen PS (2011b) Testing the right target and right drug at the right stage. Sci Transl Med 3: 111cm133","journal-title":"Sci Transl Med"},{"key":"BFEMMM202114408_CR132","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P (2014) The A4 study: stopping AD before symptoms begin? Sci Transl Med 6: 228fs213","journal-title":"Sci Transl Med"},{"key":"BFEMMM202114408_CR133","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","volume":"77","author":"RA Sperling","year":"2020","unstructured":"Sperling RA, Donohue MC, Raman R, Sun CK, Yaari R, Holdridge K, Siemers E, Johnson KA, Aisen PS, A4 Study Team (2020) Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol 77: 735\u2013745","journal-title":"JAMA Neurol"},{"key":"BFEMMM202114408_CR134","doi-asserted-by":"crossref","first-page":"e1390","DOI":"10.1212\/WNL.0000000000006318","volume":"91","author":"P Steinacker","year":"2018","unstructured":"Steinacker P, Anderl\u2010Straub S, Diehl\u2010Schmid J, Semler E, Uttner I, von Arnim CAF, Barthel H, Danek A, Fassbender K, Fliessbach K et\u00a0al (2018) Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology 91: e1390\u2013e1401","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13195-020-00738-8","volume":"12","author":"J Stockmann","year":"2020","unstructured":"Stockmann J, Verberk IMW, Timmesfeld N, Denz R, Budde B, Lange\u2010Leifhelm J, Scheltens P, van der Flier WM, Nabers A, Teunissen CE et\u00a0al (2020) Amyloid\u2010beta misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimers Res Ther 12: 169","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114408_CR136","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF Abeta 42 levels correlate with amyloid\u2010neuropathology in a population\u2010based autopsy study. Neurology 60: 652\u2013656","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR137","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Suarez\u2010Calvet","year":"2020","unstructured":"Suarez\u2010Calvet M, Karikari TK, Ashton NJ, Lantero Rodriguez J, Mila\u2010Aloma M, Gispert JD, Salvado G, Minguillon C, Fauria K, Shekari M et\u00a0al (2020) Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the\u00a0initial stages of the preclinical Alzheimer's continuum when only\u00a0subtle changes in Abeta pathology are detected. EMBO Mol Med 12: e12921","journal-title":"EMBO Mol Med"},{"key":"BFEMMM202114408_CR138","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jalz.2013.01.007","volume":"10","author":"S Swaminathan","year":"2014","unstructured":"Swaminathan S, Risacher SL, Yoder KK, West JD, Shen L, Kim S, Inlow M, Foroud T, Jagust WJ, Koeppe RA et\u00a0al (2014) Association of plasma and cortical amyloid beta is modulated by APOE epsilon4 status. Alzheimers Dement 10: e9\u2013e18","journal-title":"Alzheimers Dement"},{"key":"BFEMMM202114408_CR139","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1006\/bbrc.1994.2740","volume":"205","author":"A Tamaoka","year":"1994","unstructured":"Tamaoka A, Kondo T, Odaka A, Sahara N, Sawamura N, Ozawa K, Suzuki N, Shoji S, Mori H (1994) Biochemical evidence for the long\u2010tail form (A beta 1\u201342\/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 205: 834\u2013842","journal-title":"Biochem Biophys Res Commun"},{"key":"BFEMMM202114408_CR140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid {beta}\u2010amyloid 42 and tau proteins as biomarkers of Alzheimer\u2010type pathologic changes in the brain. Arch Neurol 66: 382\u2013389","journal-title":"Arch Neurol"},{"key":"BFEMMM202114408_CR141","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","volume":"12","author":"H Tatebe","year":"2017","unstructured":"Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M, Kondo M, Allsop D, Tokuda T (2017) Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case\u2010control studies including patients with Alzheimer's disease and down syndrome. Mol Neurodegener 12: 63","journal-title":"Mol Neurodegener"},{"key":"BFEMMM202114408_CR142","doi-asserted-by":"crossref","first-page":"fcab136","DOI":"10.1093\/braincomms\/fcab136","volume":"3","author":"J Therriault","year":"2021","unstructured":"Therriault J, Benedet AL, Pascoal TA, Lussier FZ, Tissot C, Karikari TK, Ashton NJ, Chamoun M, Bezgin G, Mathotaarachchi S et\u00a0al (2021) Association of plasma P\u2010tau181 with memory decline in non\u2010demented adults. Brain Commun 3: fcab136","journal-title":"Brain Commun"},{"key":"BFEMMM202114408_CR143","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, Heuer H, Spina S et\u00a0al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med 26: 387\u2013397","journal-title":"Nat Med"},{"key":"BFEMMM202114408_CR144","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, Spina S, Allen IE, Cobigo Y, Heuer H et\u00a0al (2021a) Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 20: 739\u2013752","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR145","doi-asserted-by":"crossref","first-page":"9736","DOI":"10.1038\/s41598-021-89004-x","volume":"11","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, Verberk IMW, Vanbrabant J, Koelewijn A, Heijst H, Scheltens P, van der Flier W, Vanderstichele H, Stoops E, Teunissen CE (2021b) Highly specific and ultrasensitive plasma test detects Abeta(1\u201342) and Abeta(1\u201340) in Alzheimer's disease. Sci Rep 11: 9736","journal-title":"Sci Rep"},{"key":"BFEMMM202114408_CR146","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/alzrt162","volume":"5","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Shaw LM, Trojanowski JQ (2013) Plasma amyloid beta measurements \u2010 a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther 5: 8","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114408_CR147","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3233\/JAD-200463","volume":"77","author":"G Triana\u2010Baltzer","year":"2020","unstructured":"Triana\u2010Baltzer G, Van Kolen K, Theunis C, Moughadam S, Slemmon R, Mercken M, Galpern W, Sun H, Kolb H (2020) Development and validation of a high sensitivity assay for measuring p217 + tau in cerebrospinal fluid. J Alzheimers Dis 77: 1417\u20131430","journal-title":"J Alzheimers Dis"},{"key":"BFEMMM202114408_CR148","volume":"13","author":"G Triana\u2010Baltzer","year":"2021","unstructured":"Triana\u2010Baltzer G, Moughadam S, Slemmon R, Van Kolen K, Theunis C, Mercken M, Kolb HC (2021) Development and validation of a high\u2010sensitivity assay for measuring p217+tau in plasma. Alzheimers Dement (Amst) 13: e12204","journal-title":"Alzheimers Dement (Amst)"},{"key":"BFEMMM202114408_CR149","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1515\/CCLM.2006.258","volume":"44","author":"H Vanderstichele","year":"2006","unstructured":"Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, B\u00fcrger K, Parnetti L, Lanari A et\u00a0al (2006) Analytical\u00a0performance and clinical utility of the INNOTEST PHOSPHO\u2010TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 44: 1472\u20131480","journal-title":"Clin Chem Lab Med"},{"key":"BFEMMM202114408_CR150","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, Scheltens P, Teunissen CE, van der Flier WM (2018) Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 84: 648\u2013658","journal-title":"Ann Neurol"},{"key":"BFEMMM202114408_CR151","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2020.01.007","volume":"89","author":"IMW Verberk","year":"2020","unstructured":"Verberk IMW, Hendriksen HMA, van Harten AC, Wesselman LMP, Verfaillie SCJ, van den Bosch KA, Slot RER, Prins ND, Scheltens P, Teunissen CE et\u00a0al (2020a) Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiol Aging 89: 99\u2013107","journal-title":"Neurobiol Aging"},{"key":"BFEMMM202114408_CR152","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","volume":"12","author":"IMW Verberk","year":"2020","unstructured":"Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, Zwan MD, Verfaillie SCJ, Ossenkoppele R, Barkhof F et\u00a0al (2020b) Combination of plasma amyloid beta(1\u201342\/1\u201040) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther 12: 118","journal-title":"Alzheimers Res Ther"},{"key":"BFEMMM202114408_CR153","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","volume":"2","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, Scheltens P, Teunissen C, van der Flier W (2021) Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic\u2010based cohort study. Lancet Healthy Longev 2: e87\u2013e95","journal-title":"Lancet Healthy Longev"},{"key":"BFEMMM202114408_CR154","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","volume":"90","author":"F Verde","year":"2019","unstructured":"Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, Tumani H, von Arnim CAF, Dorst J, Feneberg E et\u00a0al (2019) Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 90: 157\u2013164","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFEMMM202114408_CR155","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","volume":"89","author":"PSJ Weston","year":"2017","unstructured":"Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, Druyeh R, Malone IB, Ahsan RL, Pemberton H et\u00a0al (2017) Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology 89: 2167\u20132175","journal-title":"Neurology"},{"key":"BFEMMM202114408_CR156","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1474-4422(03)00666-5","volume":"3","author":"P Whitehouse","year":"2004","unstructured":"Whitehouse P, Frisoni GB, Post S (2004) Breaking the diagnosis of dementia. Lancet Neurol 3: 124\u2013128","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR157","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","volume":"15","author":"B Winblad","year":"2016","unstructured":"Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo\u2010Minguez A, Dubois B, Edvardsson D, Feldman H et\u00a0al (2016) Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol 15: 455\u2013532","journal-title":"Lancet Neurol"},{"key":"BFEMMM202114408_CR158","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028263","volume":"6","author":"H Zetterberg","year":"2011","unstructured":"Zetterberg H, Mortberg E, Song L, Chang L, Provuncher GK, Patel PP, Ferrell E, Fournier DR, Kan CW, Campbell TG et\u00a0al (2011) Hypoxia due to cardiac arrest induces a time\u2010dependent increase in serum amyloid beta levels in humans. PLoS One 6: e28263","journal-title":"PLoS One"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202114408.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/emmm.202114408","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.202114408\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.202114408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202114408.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:37:00Z","timestamp":1779086220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.202114408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":157,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,11]]}},"alternative-id":["BFEMMM202114408"],"URL":"https:\/\/doi.org\/10.15252\/emmm.202114408","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]},"assertion":[{"value":"8 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AL, NMC, SJ, and SP report no disclosures. JLD is a former employee of Eli Lilly and Company. OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, and Euroimmun. In the past 2 years, he has received consultancy\/speaker fees (paid to the institution) from Biogen and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"EMMM202114408"}}